Neurological Disorder Diagnostics

Global Neurological Disorder Diagnostics Market to Reach US$13.6 Billion by 2030

The global market for Neurological Disorder Diagnostics estimated at US$9.9 Billion in the year 2024, is expected to reach US$13.6 Billion by 2030, growing at a CAGR of 5.6% over the analysis period 2024-2030. Imaging Diagnostics, one of the segments analyzed in the report, is expected to record a 4.6% CAGR and reach US$8.6 Billion by the end of the analysis period. Growth in the In-Vitro Diagnostics segment is estimated at 7.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.7 Billion While China is Forecast to Grow at 8.6% CAGR

The Neurological Disorder Diagnostics market in the U.S. is estimated at US$2.7 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.7 Billion by the year 2030 trailing a CAGR of 8.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.8% and 5.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.6% CAGR.

Global Neurological Disorder Diagnostics Market - Key Trends & Drivers Summarized

How Is Evolving Disease Complexity Reshaping Diagnostic Approaches?

Neurological disorders encompass a wide range of conditions such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, epilepsy, and stroke. These disorders often present with overlapping symptoms, making accurate diagnosis increasingly complex. As the understanding of neurodegeneration advances, diagnostics are shifting toward early-stage identification and personalized evaluation. Traditional diagnostic tools like CT scans and MRIs are now being complemented by advanced techniques including PET imaging, cerebrospinal fluid analysis, and electrophysiological monitoring.

Molecular diagnostics, particularly those using biomarkers for detecting amyloid plaques or tau proteins, are gaining importance in identifying neurodegenerative conditions well before the onset of clinical symptoms. This push for earlier and more precise detection has been supported by advances in proteomics, genomics, and imaging informatics. Integration of digital platforms and AI-based analytics is also enabling clinicians to distinguish between different neurological conditions more efficiently, even when symptoms are ambiguous or evolve over time.

What Role Does Technology Play in Expanding Diagnostic Accuracy?

Technological integration has significantly enhanced the accuracy and scope of neurological diagnostics. High-resolution imaging tools now provide detailed insights into brain morphology, vascular anomalies, and functional disturbances. MRI techniques like diffusion tensor imaging and functional MRI are increasingly used for mapping brain activity, particularly in epilepsy and traumatic brain injury assessments. Meanwhile, EEG and MEG technologies continue to be vital for real-time neuroelectrical monitoring in epilepsy, sleep disorders, and encephalopathies.

Another key trend is the rise of non-invasive and portable diagnostic devices, which offer convenience in outpatient or home-based settings. Wearable neuro-monitoring systems and mobile EEG solutions are helping track brain activity continuously, allowing physicians to identify intermittent abnormalities that may not appear during standard clinical tests. Cloud connectivity and remote diagnostics are further widening access to specialized evaluations, particularly in underserved or rural areas.

Why Are Personalized Diagnostics Becoming a Clinical Priority?

Growing emphasis on personalized medicine is transforming how neurological diagnostics are interpreted and applied. With neurological disorders showing significant heterogeneity in progression and response to treatment, diagnostics are now being tailored to individual risk profiles. This includes using genetic screening to detect hereditary neurodegenerative disorders, such as Huntington’s disease or familial Alzheimer’s, as well as leveraging machine learning algorithms to assess disease trajectory based on cognitive test patterns and imaging data.

Multimodal diagnostics, which combine data from brain scans, neuropsychological assessments, fluid biomarkers, and genetic tests, are being increasingly deployed in clinical trials and research programs. These approaches not only help in early disease detection but also support better treatment selection, response monitoring, and prognosis prediction. Pharmaceutical companies are also collaborating with diagnostics developers to embed companion diagnostics into neurology-focused drug development programs.

Growth in the neurological disorder diagnostics market is driven by several factors.

Increasing global burden of neurodegenerative and neurovascular disorders, driven by aging populations and rising lifestyle-related risk factors, has created strong demand for accurate and early-stage diagnostics. Advancements in imaging technology, biomarker discovery, and digital diagnostic platforms have made evaluations more reliable and accessible. Integration of AI and data analytics into neurodiagnostic systems is further improving diagnostic precision, especially in complex cases. Rising investment in neuroscience research and the growing availability of specialized diagnostic centers are also supporting market expansion. Adoption of home-based neurological assessment tools, along with regulatory support for early intervention strategies, continues to encourage innovation in diagnostic product development across healthcare systems.

SCOPE OF STUDY:

The report analyzes the Neurological Disorder Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product (Imaging Diagnostics, In-Vitro Diagnostics); Disorder (Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder, Paraproteinemic Neuropathies Disorder); End-Use (Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use, Ambulatory Surgery Centers End-Use)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

• Abbott Laboratories
• Advanced Brain Monitoring, Inc.
• Biogen Inc.
• Bio-Rad Laboratories, Inc.
• Canon Medical Systems Corporation
• Elekta AB
• F. Hoffmann-La Roche Ltd
• Fujifilm Holdings Corporation
• GE HealthCare
• Hologic, Inc.
• IXICO plc
• Lifelines Neuro Company LLC
• Masimo Corporation
• Medtronic plc
• NeuroPace, Inc.
• Natus Medical Incorporated
• Nihon Kohden Corporation
• Philips Healthcare (Koninklijke Philips)
• QIAGEN N.V.
• Siemens Healthineers AG

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.